智通财经APP获悉，和铂医药-B(02142)绩后涨近5%，高见13.55港元再创新高。截至发稿，涨3.35%，报13.28港元，成交额3612.95万港元。
消息面上，和铂医药公布中期业绩，收入约1.01亿美元，同比增长约3.27倍；期内溢利7299.9万美元，同比增长51.25倍。其中，分子许可费收入由2080万美元增加至9370万美元，主要由于与全球制药公司的战略合作及新取得的创新产品对外授权。同时，研究服务及技术许可费收入由290万美元增长164.9%至760万美元。
公告显示，于2025年3月，该公司与阿斯利康订立全球战略合作关系，共同研发针对免疫性疾病、肿瘤及其他多种疾病的新一代多特异性抗体。该战略合作关系包括利用和铂医药的专有全人源抗体技术平台Harbour Mice在多个治疗领域进行多个项目的授权许可选择权。作为回报，该公司将获得最多约46 亿美元的预付款及里程碑付款以及按净销售额计算的分层特许权使用费。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.